Abstract:Propose: Instant blood-mediated inflammatory reaction (IBMIR) causes significant peri-transplant islet damage following intraportal transplantation. IBMIR is initiated and perpetuated by a cascade of cellular and soluble innate immune responses, including high-mobility group box 1, tissue factor, macrophage chemoattractant protein-1, and interleukin-1β. Thrombomodulin (TM) regulates coagulation and suppresses inflammatory functions of neutrophils and macrophages while CD47 inhibits phagocytosis by macrophages, reducing inflammation and tissue damage. The main objective of this study was to exploit the immunomodulatory efficacy of these two molecules to mitigate IBMIR. Method: Pancreatic islets were biotinylated, followed by transient and positional display on their surface novel forms of TM (SA-TM) and CD47 (SA-CD47) chimeric with a modified form of streptavidin by taking the advantage of strong affinity between biotin and streptavidin. The viability and function of the engineered islets as well as their ability to mitigate IBMIR were assessed. Co-engineered islets were transplanted intraportally into streptozotocin diabetic syngeneic recipients (150 IEQ/mouse). Unmodified islets or islets engineered with SA-TM served as control. Blood glucose levels were monitored and graft function was assessed using an intraperitoneal glucose tolerance test. Flow cytometry and transcriptomic analysis were conducted on graft recipients at different times post-transplantation. Results: Islets were successfully engineered with SA-TM/SA-CD47 combination without affecting their viability and function. SA-TM/SA-CD47 on rat splenocytes inhibited phagocytosis by mouse macrophages in vitro. Similarly, bone marrow cells engineered with SA-TM/SA-CD47 were resistant to clearance in allogeneic hosts. In an ex vivo blood loop assay, SA-TM/SA-CD47 prevented islet damage associated with the down-regulation of various inflammatory mediators driving IBMIR. In a syngeneic minimal mass model of intraportal islet transplantation, SA-TM/SA-CD47-engineered islets had enhanced engraftment as compared with SA-TM-engineered islets or unmodified islets. The enhanced engraftment was associated with a significant decrease in intragraft proinflammatory cells and transcritps involved in IBMIR. Conclusion: Engineering islets to codisplay on their surface SA-TM and SA-CD47 molecules as regulators of innate immune responses effectively inhibits peri-transplant islet graft loss with implications for both autologous and allogeneic islet transplantation. Funded in parts by NIH R01AI121281 award.

Impact of Prevascularization on Immunological Environment and Early Engraftment in Subcutaneous Islet Transplantation

Effects of pre-vascularization of tissue-engineered constructs on the survival of transplanted pancreaticislets

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

A Gelatin Hydrogel Nonwoven Fabric Combined With Adipose Tissue–Derived Stem Cells Enhances Subcutaneous Islet Engraftment

Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression

Efficient vascular and neural engraftment of stem cell-derived islets

High-Efficiency, Prevascularization-Free Macroencapsulation System for Subcutaneous Transplantation of Pancreatic Islets for Enhanced Diabetes Treatment

A novel prevascularized tissue-engineered chamber as a site for allogeneic and xenogeneic islet transplantation to establish a bioartificial pancreas

Molecular Retention Limitations for Prevascularized Subcutaneous Sites for Islet Transplantation

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

Comprehensive analysis of gene expression of isolated pancreatic islets during pretransplant culture

Improvement of islet transplantation by the fusion of islet cells with functional blood vessels

Reversal of Hyperglycemia by Subcutaneous Islet Engraftment Using an Atelocollagen Sponge as a Scaffold

Acceptance of Murine Islet Allografts Without Immunosuppression in Inguinal Subcutaneous White Adipose Tissue Pretreated With bFGF

The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

Engineering Pancreatic Islets to Transiently Codisplay on Their Surface Thrombomodulin and CD47 Immunomodulatory Proteins as a Means of Mitigating Instant Blood-Mediated Inflammatory Reaction following Intraportal Transplantation

Co-transplantation of human adipose-derived mesenchymal stem cells with neonatal porcine islets within a prevascularized subcutaneous space augments the xenograft function

Enhancement of Subcutaneous Islet Transplant Performance by Collagen 1 Gel

201.1: Co-engineering Pancreatic Islets with Novel Forms of Thrombomodulin and CD47 As an Effective Means of Mitigating Instant Blood-Mediated Inflammatory Reaction

Biomaterial-assisted strategies to improve islet graft revascularization and transplant outcomes

Inguinal Subcutaneous White Adipose Tissue (ISWAT) Transplantation Model of Murine Islets